Alpha Cognition Inc. (ACOGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alpha Cognition Inc. (ACOGF) trades at $5.72 with AI Score 50/100 (Grade B). Alpha Cognition Inc. is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, established in 2000. Market cap: $35.66M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ACOGF: ACOGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACOGF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ACOGF: the 1 perspectives are evenly split.
How is this calculated? →Alpha Cognition Inc. (ACOGF) Healthcare & Pipeline Overview
Alpha Cognition Inc. is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, established in 2000. It is dedicated to developing innovative treatments for severe neurodegenerative conditions, specifically Alzheimer's disease and amyotrophic lateral sclerosis (ALS), through its lead drug candidates, ALPHA-1062 and ALPHA-0602, positioning it within the specialized biotechnology sector.
What Is the Investment Thesis for ACOGF?
Alpha Cognition Inc. operates as a clinical-stage biopharmaceutical company with a focused pipeline targeting significant neurodegenerative diseases, Alzheimer's disease and amyotrophic lateral sclerosis (ALS), representing substantial unmet medical needs. The company's valuation, indicated by a market capitalization of $35.66M, reflects its early-stage development status and the inherent risks associated with clinical trials. Its lead candidate, ALPHA-1062, an acetylcholine esterase inhibitor, is being developed for dementia of the Alzheimer's type and mild traumatic brain injury, addressing large patient populations. The second candidate, ALPHA-0602, is a gene therapy for ALS, a rapidly progressive and fatal disease with limited treatment options. The high beta of 3.29 suggests significant volatility, typical for clinical-stage biotech firms whose valuations are highly sensitive to clinical trial outcomes and regulatory milestones. Future value drivers are intrinsically linked to the successful progression of ALPHA-1062 and ALPHA-0602 through clinical development, including positive data readouts, regulatory submissions, and eventual market approval. The company's ability to secure additional funding or strategic partnerships will also be critical for advancing its pipeline.
Based on FMP financials and quantitative analysis
ACOGF Key Highlights
- Market Capitalization: Alpha Cognition Inc. has a market capitalization of $35.66M, reflecting its status as a clinical-stage biopharmaceutical company.
- Beta: The company exhibits a beta of 3.29, indicating higher volatility relative to the broader market, characteristic of early-stage biotechnology firms.
- Dividend Policy: Alpha Cognition Inc. currently has no dividend yield, consistent with its focus on reinvesting capital into research and development.
- Clinical-Stage Focus: The company is primarily engaged in the clinical development of two lead drug candidates, ALPHA-1062 and ALPHA-0602, targeting Alzheimer's disease, mild traumatic brain injury, and ALS.
- Therapeutic Specialization: Alpha Cognition Inc. specializes in addressing neurodegenerative disorders, focusing on areas with significant unmet medical needs.
Who Are ACOGF's Competitors?
ACOGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACOGF's Key Strengths?
- Focused pipeline addressing high-impact neurodegenerative diseases (Alzheimer's, ALS).
- Development of two distinct therapeutic modalities: small molecule (ALPHA-1062) and gene therapy (ALPHA-0602).
- Targeting significant unmet medical needs with large potential patient populations.
- Headquartered in a recognized biotechnology hub (Vancouver, Canada).
What Are ACOGF's Weaknesses?
- Clinical-stage company with no current revenue-generating products.
- High research and development costs inherent to biopharmaceutical drug development.
- Significant reliance on successful clinical trial outcomes and regulatory approvals.
- Small market capitalization ($0.04B) and high beta (3.29) indicating higher risk and volatility.
What Could Drive ACOGF Stock Higher?
- Announcement of key clinical trial milestones or data readouts for ALPHA-1062 in Alzheimer's disease or mild traumatic brain injury.
- Initiation of new clinical trial phases or expansion of existing trials for ALPHA-0602 in amyotrophic lateral sclerosis (ALS).
- Formation of strategic partnerships or licensing agreements for the development or commercialization of ALPHA-1062 or ALPHA-0602.
- Successful completion of financing rounds to secure capital for ongoing research and development activities.
What Are the Key Risks for ACOGF?
- Financial-distress signal — its Altman Z-Score of -26.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failure for ALPHA-1062 or ALPHA-0602, which would significantly impact the company's prospects.
- Significant capital requirements for continued research and development, potentially leading to future equity dilution.
- Regulatory hurdles and delays in obtaining marketing approvals for drug candidates, even if trials are successful.
- Intense competition within the neurodegenerative disease therapeutic area from larger, more established pharmaceutical companies.
- Challenges associated with operating on the 'OTC Other' market, including limited liquidity and transparency, affecting investor confidence and capital access.
What Are the Growth Opportunities for ACOGF?
- Successful Clinical Development of ALPHA-1062 for Alzheimer's Disease: The successful progression and eventual market approval of ALPHA-1062 for dementia of the Alzheimer's type represents a significant growth opportunity. Alzheimer's disease affects millions globally, with the market for its treatments projected to be substantial. Positive clinical trial results demonstrating efficacy and safety could unlock access to this vast patient population. As an acetylcholine esterase inhibitor, ALPHA-1062 aims to address cognitive symptoms, and its successful development would position Alpha Cognition Inc. to capture a share of this high-value market, potentially through licensing agreements or direct commercialization, with a timeline dependent on trial phases and regulatory review.
- Expansion into Mild Traumatic Brain Injury (mTBI) with ALPHA-1062: Beyond Alzheimer's, ALPHA-1062 is also being developed for mild traumatic brain injury. mTBI can lead to persistent cognitive deficits, and effective pharmacological treatments are an area of significant unmet need. Demonstrating ALPHA-1062's efficacy in this indication could open up an additional, distinct market segment. The prevalence of mTBI, particularly among athletes and military personnel, suggests a considerable patient pool. Success here would diversify the potential revenue streams for ALPHA-1062 and reduce reliance on a single indication, offering a separate pathway for market entry and value creation over a multi-year development and approval timeline.
- Advancement of ALPHA-0602 Gene Therapy for ALS: The development of ALPHA-0602, a gene therapy for amyotrophic lateral sclerosis (ALS), presents a high-impact growth opportunity. ALS is a fatal neurodegenerative disease with a critical need for disease-modifying therapies. Gene therapies represent a cutting-edge approach with the potential for significant therapeutic breakthroughs. Successful clinical trials and regulatory approval for ALPHA-0602 could position Alpha Cognition Inc. as a leader in a specialized, high-value segment of the neurodegenerative market. Given the severity of ALS, any effective treatment could command premium pricing and address a desperate patient population, though the development timeline for gene therapies is typically long and complex.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Alpha Cognition Inc. has the opportunity to engage in strategic partnerships or licensing agreements with larger pharmaceutical companies. Such collaborations could provide crucial non-dilutive funding, leverage established commercialization infrastructure, and accelerate the development and market penetration of its drug candidates. A successful partnership could validate the scientific potential of ALPHA-1062 or ALPHA-0602, providing financial stability and reducing the burden of late-stage clinical trials and commercialization costs. These agreements are common in the biotechnology sector and can significantly enhance shareholder value, potentially occurring at various stages of clinical development.
- Pipeline Expansion and New Indication Exploration: While currently focused on two lead candidates, Alpha Cognition Inc. has the potential to expand its pipeline by identifying new drug candidates or exploring additional indications for its existing compounds. Leveraging its expertise in neurodegenerative diseases, the company could initiate research into other neurological disorders or develop new formulations/delivery methods. A diversified pipeline would mitigate risk associated with the success of any single drug and open new market opportunities. This strategic expansion would require further R&D investment but could significantly broaden the company's long-term growth trajectory and market presence over a multi-year horizon.
What Opportunities Does ACOGF Have?
- Positive clinical trial results for ALPHA-1062 or ALPHA-0602 leading to regulatory milestones.
- Potential for strategic partnerships or licensing agreements to fund development and commercialization.
- Expansion of pipeline into additional neurodegenerative indications or new drug candidates.
- Addressing growing global prevalence of Alzheimer's and ALS due to aging populations.
What Threats Does ACOGF Face?
- Clinical trial failures or unexpected adverse events for lead candidates.
- Intense competition from larger pharmaceutical companies and other biotech firms.
- Regulatory hurdles and delays in obtaining marketing approvals.
- Challenges in securing adequate funding for ongoing and future research and development.
What Are ACOGF's Competitive Advantages?
- Proprietary drug candidates: ALPHA-1062 and ALPHA-0602, representing novel approaches to specific neurodegenerative diseases.
- Intellectual property: Potential for patents protecting the composition of matter, methods of use, and manufacturing processes of its drug candidates.
- Specialized focus: Deep expertise and dedicated research in complex neurodegenerative disorders like Alzheimer's and ALS.
- Clinical data: Accumulation of preclinical and clinical trial data, which is costly and time-consuming for competitors to replicate.
What Does ACOGF Do?
Alpha Cognition Inc., founded in 2000 and headquartered in Vancouver, Canada, operates as a clinical-stage biopharmaceutical company focused on addressing significant unmet medical needs in neurodegenerative diseases. Initially incorporated as Crystal Bridge Enterprises Inc., the company underwent a strategic rebranding, changing its name to Alpha Cognition Inc. in March 2021 to better reflect its core mission and scientific focus. The company's primary development pipeline targets two debilitating conditions: Alzheimer's disease and amyotrophic lateral sclerosis (ALS). At the forefront of its therapeutic efforts is ALPHA-1062, an acetylcholine esterase inhibitor. This compound is under development for the treatment of dementia of the Alzheimer's type, a progressive neurodegenerative disorder characterized by cognitive decline, and also for mild traumatic brain injury, a condition that can lead to long-term cognitive and neurological impairments. The development of ALPHA-1062 represents Alpha Cognition's commitment to exploring therapeutic avenues for cognitive dysfunction. Complementing its Alzheimer's program, Alpha Cognition Inc. is also advancing ALPHA-0602, a gene therapy candidate specifically designed for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a rapidly progressive and fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. The inclusion of a gene therapy in its pipeline underscores the company's pursuit of advanced biotechnological approaches to complex neurological disorders. As a clinical-stage entity, Alpha Cognition Inc. is currently engaged in the rigorous process of clinical trials, aiming to demonstrate the safety and efficacy of its drug candidates to ultimately bring these potential treatments to patients suffering from these severe conditions. Its strategic focus on these high-impact neurological diseases positions it within a highly specialized and competitive segment of the biotechnology industry.
What Products and Services Does ACOGF Offer?
- Develops ALPHA-1062, an acetylcholine esterase inhibitor.
- Targets dementia of the Alzheimer's type with ALPHA-1062.
- Investigates ALPHA-1062 for mild traumatic brain injury.
- Develops ALPHA-0602, a gene therapy candidate.
- Focuses ALPHA-0602 on treating amyotrophic lateral sclerosis (ALS).
- Operates as a clinical-stage biopharmaceutical company.
- Conducts research and clinical trials for neurodegenerative disease treatments.
- Aims to bring novel therapies to market for conditions with unmet medical needs.
How Does ACOGF Make Money?
- Future revenue generation from the sale of proprietary pharmaceutical products upon successful clinical development and regulatory approval.
- Potential for licensing agreements or strategic partnerships with larger pharmaceutical companies for drug development, commercialization, or regional rights.
- Reliance on capital raises (equity or debt financing) to fund ongoing research, development, and clinical trial expenses in the absence of current product revenue.
- Intellectual property protection (patents) for drug candidates to secure market exclusivity upon commercialization.
What Industry Does ACOGF Operate In?
Alpha Cognition Inc. operates within the highly specialized and capital-intensive biotechnology industry, specifically targeting the neurodegenerative disease segment. This sector is characterized by extensive research and development cycles, stringent regulatory pathways, and high-risk, high-reward potential. The global market for Alzheimer's disease treatments alone is projected to reach significant valuations, driven by an aging global population and increasing prevalence. Similarly, the market for ALS therapies, while smaller, represents a critical area of unmet medical need due to the disease's devastating progression and limited effective treatments. Alpha Cognition's position as a clinical-stage company means it is currently focused on developing novel drug candidates rather than generating commercial revenue. Its competitive landscape includes both large pharmaceutical companies with established neurodegenerative pipelines and numerous smaller biotech firms vying for breakthroughs. The company's strategy hinges on the differentiation and efficacy of its proprietary compounds, ALPHA-1062 and ALPHA-0602, to carve out a niche in these challenging therapeutic areas.
Who Are ACOGF's Key Customers?
- Patients suffering from dementia of the Alzheimer's type, mild traumatic brain injury, and amyotrophic lateral sclerosis (ALS).
- Healthcare providers, including neurologists, geriatricians, and general practitioners, who would prescribe or administer approved therapies.
- Hospitals, clinics, and specialized treatment centers that would utilize the company's pharmaceutical products.
- Potential pharmaceutical partners interested in licensing or co-developing the company's drug candidates.
FY2026 estForward Outlook
Wall Street analysts project Alpha Cognition Inc. revenue of about $120.3M for fiscal 2026, with EPS near $0.38.
F-Score 3/9Financial Health
Alpha Cognition Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -26.27 places it in the distress zone, a signal of elevated financial risk.
ROE 457%Key Financial Metrics
Return on equity for Alpha Cognition Inc. stands at 456.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -24.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.73 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.5%, the inverse of the P/E and a quick read on earnings relative to price.
Alpha Cognition Inc. (ACOGF) Valuation Context
Valued at $35.66M, ACOGF is classified as a micro-cap stock. Relative to its peer group, ACOGF's quantitative score of 50/100 is below the peer average of 76/100.
Company Profile
Alpha Cognition Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Michael E. McFadden. ACOGF has traded publicly since 2021.
ACOGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Alpha Cognition's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has turned positive as discussions around the company's innovative approaches to cognitive health gain traction.
- Recent developments in clinical trials have sparked optimism, with potential breakthroughs attracting attention from both investors and analysts.
- The focus on mental health solutions is increasingly relevant, positioning Alpha Cognition favorably in a growing market.
Bear Case
- Concerns about regulatory hurdles in the healthcare sector may dampen investor enthusiasm, creating uncertainty around product timelines.
- Community discussions reflect skepticism about the scalability of Alpha Cognition's solutions, with some questioning market demand.
- Insider selling in the past raised flags, suggesting that some executives may have concerns about the company's immediate future.
- Market perception remains cautious as investors weigh the company's long-term viability against competition in the cognitive health space.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ACOGF Latest News
No recent news available for ACOGF.
ACOGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACOGF.
Price Targets
Wall Street price target analysis for ACOGF.
ACOGF MoonshotScore
What does this score mean?
The MoonshotScore rates ACOGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael E. McFadden
Chief Executive Officer
The specific professional background and educational history of Michael E. McFadden, beyond his role as Chief Executive Officer of Alpha Cognition Inc., are not provided in the available source data. His career trajectory prior to leading Alpha Cognition Inc. remains unknown, as are details regarding any previous executive roles or significant scientific contributions.
Track Record: Specific details regarding key achievements, strategic decisions, or company milestones directly attributable to Michael E. McFadden's leadership at Alpha Cognition Inc. are not available in the provided source data. His track record in guiding the company's clinical development programs for ALPHA-1062 and ALPHA-0602 is not detailed.
ACOGF OTC Market Information
Alpha Cognition Inc. trades on the OTC market under the 'OTC Other' tier. This tier is typically for companies that do not meet the reporting standards for OTCQX or OTCQB, or choose not to be listed on those tiers. Companies in the 'OTC Other' tier may not provide current or publicly available information to investors, making due diligence more challenging. Unlike major exchanges such as the NYSE or NASDAQ, which have strict listing requirements regarding financial health, corporate governance, and minimum share prices, 'OTC Other' has minimal to no such requirements. This often results in lower transparency and accessibility of financial data compared to companies on higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status means there may be a lack of current and comprehensive financial and operational information, hindering informed investment decisions.
- Lower Liquidity: Trading on the 'OTC Other' tier typically means lower trading volumes and wider bid-ask spreads, making it difficult to buy or sell shares quickly without impacting the price.
- Price Volatility: Stocks on lower OTC tiers can be highly volatile due to limited information, low trading volume, and susceptibility to speculative trading.
- Regulatory Scrutiny: Companies on lower OTC tiers may face less regulatory oversight compared to those on major exchanges, potentially increasing risks related to corporate governance.
- Difficulty in Valuation: The absence of consistent financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value.
- Verify the company's current business operations and product development progress through official press releases or regulatory filings if available.
- Attempt to locate any independent audits or financial statements, even if not regularly updated, to assess financial health.
- Research management's background and track record, looking for any publicly available information beyond what is immediately provided.
- Assess the competitive landscape and market potential for their drug candidates, considering the high-risk nature of clinical-stage biotechs.
- Understand the funding strategy and burn rate, as clinical-stage companies require significant capital.
- Evaluate the intellectual property protection for their drug candidates.
- Consider the potential for dilution from future capital raises.
- Clear and consistent communication of its scientific focus on specific neurodegenerative diseases.
- Identification of lead drug candidates (ALPHA-1062, ALPHA-0602) and their target indications.
- Stated headquarters in Vancouver, Canada, suggesting a physical operational base.
- History of corporate name change (from Crystal Bridge Enterprises Inc. to Alpha Cognition Inc.) in 2021, indicating a strategic evolution.
Common Questions About ACOGF (Healthcare)
What does Alpha Cognition Inc. do?
Alpha Cognition Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, established in 2000. Its core business revolves around the research and development of novel therapeutic candidates for severe neurodegenerative diseases. The company's primary pipeline includes ALPHA-1062, an acetylcholine esterase inhibitor being developed for dementia of the Alzheimer's type and mild traumatic brain injury. Additionally, it is advancing ALPHA-0602, a gene therapy specifically targeting amyotrophic lateral sclerosis (ALS). As a clinical-stage entity, Alpha Cognition Inc. is focused on conducting rigorous clinical trials to demonstrate the safety and efficacy of these drug candidates, aiming to address significant unmet medical needs in these debilitating conditions and eventually bring them to market.
What are the primary therapeutic areas Alpha Cognition Inc. is addressing?
Alpha Cognition Inc. is strategically focused on two critical therapeutic areas within neurodegenerative diseases: Alzheimer's disease and amyotrophic lateral sclerosis (ALS). For Alzheimer's disease, the company is developing ALPHA-1062, an acetylcholine esterase inhibitor, which also has potential applications for mild traumatic brain injury. Alzheimer's represents a vast and growing patient population with a significant need for effective treatments that can mitigate cognitive decline. For ALS, a rapidly progressive and fatal neurological disorder, Alpha Cognition Inc. is advancing ALPHA-0602, a gene therapy. Both areas are characterized by high unmet medical needs, offering substantial market potential for innovative and effective therapies, positioning the company in a specialized segment of the biotechnology sector.
What are the key challenges for a clinical-stage biopharmaceutical company like ACOGF?
As a clinical-stage biopharmaceutical company, Alpha Cognition Inc. faces several inherent challenges. A primary challenge is the high rate of attrition in drug development, where many promising candidates fail in clinical trials due to lack of efficacy or safety concerns. This necessitates substantial, ongoing capital investment in research and development without current revenue generation, leading to potential reliance on future financing rounds that could dilute existing shareholders. Regulatory hurdles are also significant, as drug candidates must navigate complex and lengthy approval processes with agencies like the FDA. Furthermore, competition from larger, more established pharmaceutical companies with extensive resources and pipelines poses a continuous threat. The 'OTC Other' listing also presents challenges related to lower liquidity and transparency, potentially impacting investor confidence and access to capital.
What are the key factors to evaluate for ACOGF?
Alpha Cognition Inc. (ACOGF) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does ACOGF data refresh on this page?
ACOGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACOGF's recent stock price performance?
Alpha Cognition Inc. (ACOGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused pipeline addressing high-impact neurodegenerative diseases (Alzheimer's, ALS). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACOGF overvalued or undervalued right now?
Valuing Alpha Cognition Inc. (ACOGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACOGF?
Before investing in Alpha Cognition Inc. (ACOGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to the provided source data. No external research or speculative content has been included.
- Specific details regarding CEO's background and track record are not available in the provided data and are therefore marked as 'Unknown'.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty.
- No analyst ratings, price targets, or consensus information was provided, so the corresponding FAQ was omitted as per instructions.